Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Myasthenia Gravis × inebilizumab × 30 days × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

rozanolixizumab 5 zilucoplan 3 ravulizumab 3 telitacicept 2 inebilizumab 2 fludarabine 2 Prednisone 2 Cyclophosphamide 2 thymoglobulin 1 remibrutinib 1 prednylidene 1 iptacopan 1 efgartigimod alfa 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 Prednisolone 1 Peripheral Blood Stem Cell Transplantation 1 Melphalan 1 Etoposide 1 Cytarabine 1 Cladribine 1 Carmustine 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06987539 2026-03-16

THYME

Amgen

Phase 2 Recruiting

Myasthenia Gravis

NCT04524273 2026-03-10

MINT

Amgen

Phase 3 Active not recruiting

238 enrolled 36 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡